CVR number 40641246
Industry 46.4610 Wholesale of pharmaceutical goods

Nordic Medical Solutions Scandinavia ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  4.1% 1.9% 1.3% 0.9% 2.7%  
Credit score (0-100)  50 70 80 89 60  
Credit rating  BBB A A A BBB  
Credit limit (kDKK)  0.0 4.6 324.2 443.5 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  4,390 15,648 12,208 5,186 1,806  
EBITDA  2,006 11,257 8,386 1,494 671  
EBIT  2,006 11,257 8,386 1,494 642  
Pre-tax profit (PTP)  1,841.9 11,354.1 7,834.1 868.9 682.4  
Net earnings  1,404.8 8,827.9 6,073.9 650.9 509.1  
Pre-tax profit without non-rec. items  1,842 11,354 7,834 869 682  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 220 280 0.0 0.0  
Shareholders equity total  1,455 10,283 8,529 3,856 1,509  
Interest-bearing liabilities  4,277 140 434 516 9,495  
Balance sheet total (assets)  6,947 15,207 13,447 6,684 13,051  
Net Debt  4,247 -5,847 -6,601 -346 8,938  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  4,390 15,648 12,208 5,186 1,806  
Gross profit growth  0.0% 256.5% -22.0% -57.5% -65.2%  
Employees  4 4 4 4 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% -50.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  6,947 15,207 13,447 6,684 13,051  
Balance sheet change%  0.0% 118.9% -11.6% -50.3% 95.3%  
Added value  2,006.0 11,256.9 8,386.4 1,494.3 671.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 220 59 23 -60  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  45.7% 71.9% 68.7% 28.8% 35.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  28.9% 102.6% 58.5% 15.1% 7.0%  
ROI %  35.1% 140.5% 86.4% 22.8% 8.9%  
ROE %  96.6% 150.4% 64.6% 10.5% 19.0%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  21.0% 67.7% 63.7% 57.8% 12.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  211.7% -51.9% -78.7% -23.1% 1,331.0%  
Gearing %  294.0% 1.4% 5.1% 13.4% 629.2%  
Net interest  0 0 0 0 0  
Financing costs %  7.8% 0.6% 192.7% 136.9% 0.2%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.9 4.9 3.5 2.0 0.4  
Current Ratio  1.4 6.3 4.2 2.4 1.1  
Cash and cash equivalent  29.4 5,987.1 7,034.5 862.1 557.1  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,891.9 12,622.3 10,009.4 3,771.4 1,425.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  502 2,814 2,097 374 336  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  502 2,814 2,097 374 336  
EBIT / employee  502 2,814 2,097 374 321  
Net earnings / employee  351 2,207 1,518 163 255